Search
D-Serine
go.drugbank.com/drugs/DB03929ApprovedInvestigationalWithdrawnA non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.
Canrenoic acid
go.drugbank.com/drugs/DB09015ApprovedInvestigationalWithdrawnCanrenoic acid (as the salt potassium canrenoate) is an aldosterone antagonist. Like spironolactone, it is a prodrug, which is metabolized to canrenone in the body.
Resatorvid
go.drugbank.com/drugs/DB05943InvestigationalResatorvid is an investigational compound designed for the treatment of severe sepsis.
ZD4407
go.drugbank.com/drugs/DB06539ExperimentalIt entered Phase 1 clinical trials for chronic obstructive pulmonary disease (COPD) in the United Kingdom but was discontinued during this phase in March 2003 … The drug ZD4407, an antiasthmatic developed by AstraZeneca, functions as a 5-lipoxygenase inhibitor.
VLTS-934
go.drugbank.com/drugs/DB05597InvestigationalIt was under investigation in clinical trial NCT00113009 (Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease). … VLTS-934 was developed by Valentis inc. for the treatment of Peripheral Arterial Disease (PAD).
3-Methylfentanyl
go.drugbank.com/drugs/DB01571ExperimentalIllicittimes more potent than morphine in certain cases. 3-Methylfentanyl was initially discovered in 1974 and widespread illegal use of this drug has occurred since this time. … 3-Methylfentanyl is an opioid analgesic and is an analog of the potent opioid, fentanyl. 3-Methylfentanyl is one of the most powerful opioid drugs sold illegally and is estimated to be between 400-6000
Letaxaban
go.drugbank.com/drugs/DB11984InvestigationalLetaxaban has been used in trials studying the treatment and prevention of Venous Thromboembolism and Acute Coronary Syndrome.
Categories: Factor Xa InhibitorsTL-895
go.drugbank.com/drugs/DB16471InvestigationalTL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively. … TL-895 is under investigation in several clinical trials for its safety and efficacy in various conditions: NCT04419623 (completed, COVID-19 in cancer patients), NCT02825836 (active, not recruiting, B